A detailed history of Marshall Wace, LLP transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 323,211 shares of CRVS stock, worth $1.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
323,211
Previous 74,559 333.5%
Holding current value
$1.55 Million
Previous $135,000 1163.7%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.78 - $5.92 $442,600 - $1.47 Million
248,652 Added 333.5%
323,211 $1.71 Million
Q2 2024

Aug 14, 2024

BUY
$1.36 - $2.29 $101,400 - $170,740
74,559 New
74,559 $135,000
Q3 2023

Nov 14, 2023

SELL
$1.41 - $2.97 $142,297 - $299,732
-100,920 Reduced 33.74%
198,220 $289,000
Q2 2023

Aug 14, 2023

BUY
$1.0 - $3.86 $299,140 - $1.15 Million
299,140 New
299,140 $685,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.